Sexual Hormones in Human Skin
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
1 Structure and Function of the Skin
Go Back to the Top To Order, Visit the Purchasing Page for Details 1 Chapter 1 Structure and Function of the Skin The skin is the human body’s its largest organ, covering 1.6 m2 of surface area and accounting for approximate- ly 16% of an adult’s body weight. In direct contact with the outside environment, the skin helps to maintain four essential bodily functions: ① retention of moisture and prevention of permeation or loss of other molecules, ② regulation of body temperature, ③ protection of the body from microbes and harmful external influences, and ④ sensation. To understand cutaneous biology and skin diseases, it is very important to learn the structure and functions of normal human skin. A. Skin surface The skin surface is not smooth, but is laced with multiple net- works of fine grooves called sulci cutis. These can be deep or shallow. The slightly elevated areas that are surrounded by shal- lower areas of sulci cutis are called cristae cutis. Sweat pores fed crista cutis by the sweat glands open to the cristae cutis (Fig. 1.1). The orientation of the sulci cutis, which differs depending on body location, is called the dermal ridge pattern. Fingerprints and sulcus cutis patterns on the palms and soles, which are unique to each person, are formed by the sulci cutis. Elastic fibers also run in specific directions in deeper parts of the skin, with the direction depend- aabcdefg h i j klmnopqr ing on the site. Some skin diseases, such as epidermal nevus, are known to occur along specific lines distributed over the body, the Blaschko lines (Fig. -
Safety Data Sheet
SAFETY DATA SHEET SECTION 1: PRODUCT IDENTIFICATION PRODUCT NAME DHEA (Prasterone) (Micronized) PRODUCT CODE 0733 SUPPLIER MEDISCA Inc. Tel.: 1.800.932.1039 | Fax.: 1.855.850.5855 661 Route 3, Unit C, Plattsburgh, NY, 12901 3955 W. Mesa Vista Ave., Unit A-10, Las Vegas, NV, 89118 6641 N. Belt Line Road, Suite 130, Irving, TX, 75063 MEDISCA Pharmaceutique Inc. Tel.: 1.800.665.6334 | Fax.: 514.338.1693 4509 Rue Dobrin, St. Laurent, QC, H4R 2L8 21300 Gordon Way, Unit 153/158, Richmond, BC V6W 1M2 MEDISCA Australia PTY LTD Tel.: 1.300.786.392 | Fax.: 61.2.9700.9047 Unit 7, Heritage Business Park 5-9 Ricketty Street, Mascot, NSW 2020 EMERGENCY PHONE CHEMTREC Day or Night Within USA and Canada: 1-800-424-9300 NSW Poisons Information Centre: 131 126 USES Adjuvant; Androgen SECTION 2: HAZARDS IDENTIFICATION GHS CLASSIFICATION Toxic to Reproduction (Category 2) PICTOGRAM SIGNAL WORD Warning HAZARD STATEMENT(S) Reproductive effector, prohormone. Suspected of damaging fertility or the unborn child. May cause harm to breast-fed children. Causes serious eye irritation. Causes skin and respiratory irritation. Very toxic to aquatic life with long lasting effects. AUSTRALIA-ONLY HAZARDS Not Applicable. PRECAUTIONARY STATEMENT(S) Prevention Wash thoroughly after handling. Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not breathe dusts or mists. Do not eat, drink or smoke when using this product. Avoid contact during pregnancy/while nursing. Wear protective gloves, protective clothing, eye protection, face protection. Avoid release to the environment. Response IF ON SKIN (HAIR): Wash with plenty of water. -
Dermoscopy of Aplasia Cutis Congenita: a Case Report and Review of the Literature
Dermatology Practical & Conceptual Dermoscopy of Aplasia Cutis Congenita: A Case Report and Review of the Literature Rasna Neelam1, Mio Nakamura2, Trilokraj Tejasvi2 1 University of Michigan Medical School, Ann Arbor, MI, USA 2 Department of Dermatology, University of Michigan, Ann Arbor, MI, USA Key words: aplasia cutis congenita, alopecia, dermoscopy, trichoscopy Citation: Neelam R, Nakamura M, Tejasvi T. Dermoscopy of aplasia cutis congenita: a case report and review of the literature. Dermatol Pract Concept. 2021;11(1):e2021154. DOI: https://doi.org/10.5826/dpc.1101a154 Accepted: September 28, 2020; Published: January 29, 2021 Copyright: ©2021 Neelam et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License BY-NC-4.0, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: None. Competing interests: The authors have no conflicts of interest to disclose. Authorship: All authors have contributed significantly to this publication. Corresponding author: Trilokraj Tejasvi, MD, Department of Dermatology, University of Michigan, 1910 Taubman Center, 1500 E. Medical Center Dr, Ann Arbor, MI 48109, USA Email: [email protected] Introduction throbbing, and point tenderness in one of the patches of alo- pecia. The alopecic patch had been present on the right pari- Aplasia cutis congenita (ACC) is a rare heterogeneous con- etal-occipital scalp since birth and has been stable in size and genital disorder characterized by focal or widespread absence appearance for years. Three other round patches of alopecia of the skin. had also been present since birth and remained asymptomatic. -
Vaginal Delivery System
(19) & (11) EP 2 062 568 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.05.2009 Bulletin 2009/22 A61K 9/00 (2006.01) (21) Application number: 07397042.8 (22) Date of filing: 22.11.2007 (84) Designated Contracting States: • Hanes, Vladimir AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Tarrytown, NY 10591 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE • Keinänen, Antti SI SK TR 20540 Turku (FI) Designated Extension States: • Holmberg, Svante AL BA HR MK RS 20900 Turku (FI) • Nikander, Hannu (71) Applicant: Bayer Schering Pharma Oy 21330 Paattinen (FI) 20210 Turku (FI) (74) Representative: Matilainen, Mirja Helena et al (72) Inventors: Oy Jalo Ant-Wuorinen AB, • Talling, Christine Iso Roobertinkatu 4-6 A 20610 Turku (FI) 00120 Helsinki (FI) (54) Vaginal delivery system (57) The present invention is related to an intravag- brane (3) encasing the core, said core and membrane inal delivery system for the controlled release of a pro- essentially consisting of a same or different polymer com- gestogen and an estrogen, comprising additionally a position, wherein at cast one of the cores comprises a therapeutically active or a health-promoting substance progestogen or a mixture of a progestogen and an es- (1) capable of giving and/or enhancing the protection trogen, and another core may comprise an estrogen or against bacterial and fungal infections, and/or enhancing a progestogen, and wherein the membrane or the surface the protection against sexually transmitted diseases. The of the membrane or at least one of the cores comprises delivery system consists of one or more compartments said therapeutically active or a health-promoting sub- (2,4,5), one of each comprising a core (7) and a mem- stance. -
Vargas KEA, Et Al. Hepatotoxicity Associated with Methylstenbolone and Copyright© Vargas KEA, Et Al
1. Medical Journal of Clinical Trials & Case Studies ISSN: 2578-4838 Hepatotoxicity Associated with Methylstenbolone and Stanozolol Abuse Vargas KEA*, Guaraná TA, Biccas BN, Agoglia LV, Carvalho ACG, Case Report Gismondi R and Esberard EBC Volume 2 Issue 5 Received Date: July 27, 2018 Department of Gastroenterology/Hepatology, Department of Clinical Medicine, and Published Date: September 03, 2018 Department of Pathology, Antônio Pedro University Hospital, Federal Fluminense DOI: 10.23880/mjccs-16000176 University, Rio de Janeiro, Brazil *Corresponding author: Vargas Karen Elizabeth Arce, Department of Gastroenterology/Hepatology, Department of Clinical Medicine, and Department of Pathology, Antônio Pedro University Hospital, Federal Fluminense University, Rio de Janeiro, Ernani do Amaral Peixoto Avenue, 935. Ap.901 / Cep.24020043, Brazil, Tel: 005521981584624; Email: [email protected] Abstract Background & Objectives: Drug hepatotoxicity is a major cause of liver disease. Many drugs are well known to induce liver damage. Some toxic products, like anabolic androgenic steroids, that are pharmaceutical preparations since they contain pharmaceutically active substance, are available as nutritional supplements. Many patients are used to consume these like dietary stuff. Methods: We introduce a case series of two patients who developed hepatic damage after the consumption of anabolic- androgenic steroids, accompanied by a detailed bibliographic research on this topic. Results: We present two young men who developed significant liver damage, both with hyperbilirubinemia pattern after consumption of anabolic-androgenic steroids. This was associated with considerable morbidity, although both recovered without liver transplantation. The two anabolic-androgenic steroids were being marketed as dietary supplements. Conclusions: Although not well controlled substances in Brazil, anabolic-androgenic steroids are cause of severe hepatotoxicity. -
Substrate Inhibition of 17 Beta-Hydroxysteroid Dehydrogenase Type 1 in Living Cells and Regulation Among the Steroid-Converting Enzymes in Breast Cancers
Substrate inhibition of 17 beta-hydroxysteroid dehydrogenase type 1 in living cells and regulation among the steroid-converting enzymes in breast cancers Thèse Hui Han Doctorat en médecine moléculaire Philosophiæ doctor (Ph. D.) Québec, Canada © Hui Han, 2018 Substrate inhibition of 17 beta-hydroxysteroid dehydrogenase type 1 in living cells and regulation among the steroid-converting enzymes in breast cancers Thèse Hui Han Sous la direction de : Sheng-xiang Lin, directeur de recherche RÉSUMÉ Cette étude a permis de démontrer les fonctions et les mécanismes de la 17bêta- hydroxystéroïde déshydrogénase de type 1 (17β-HSD1) et de la stéroïde sulfatase (STS) au niveau du cancer du sein, y compris la cinétique moléculaire et cellulaire, la liaison du ligand étudiée par la titration de fluorescence, la régulation des stéroïdes et la régulation mutuelle entre les enzymes stéroïdiennes et les cellules cancéreuses du sein. 1), L’inhibition de la 17β-HSD1 par son substrat a été démontrée par la cinétique enzymatique au niveau cellulaire pour la première fois, soutenant ainsi la fonction biologique de l’inhibition produite par le substrat. 2), En tant qu’inhibiteur, la dihydrotestostérone (DHT) n’a pas affecté la concentration du substrat estrone (E1) à laquelle l’activité enzymatique a commencé à diminuer, mais certaines augmentations de vitesse ont été observées, suggérant une diminution significative de l’inhibition par le substrat. 3), Les résultats de la modulation de l’ARNm ont démontré que la transcription du gène codant la 17β-HSD7 diminuait en réponse à l’inhibition de la 17β-HSD1 ou au knockdown dans les cellules du cancer du sein par la modification estradiol (E2). -
A Case of Acquired Smooth Muscle Hamartoma on the Sole
Ann Dermatol (Seoul) Vol. 21, No. 1, 2009 CASE REPORT A Case of Acquired Smooth Muscle Hamartoma on the Sole Deborah Lee, M.D., Sang-Hyun Kim, M.D., Soon-Kwon Hong, M.D., Ho-Suk Sung, M.D., Seon-Wook Hwang, M.D. Department of Dermatology, Busan Paik Hospital, College of Medicine, Inje University, Busan, Korea A smooth muscle hamartoma is a benign proliferation of INTRODUCTION smooth muscle bundles within the dermis. It arises from smooth muscle cells that are located in arrector pili muscles, Smooth muscle hamartomas (SMH) are a result of benign dartos muscles, vascular smooth muscles, muscularis proliferation of smooth muscle bundles in the dermis. SMH- mammillae and the areolae. Acquired smooth muscle associated smooth muscle cells originate from arrector hamartoma (ASMH) is rare, with only 10 such cases having pili-, dartos-, vulvar-, mammillary- and vascular wall- been reported in the English medical literature to date. Most muscles1-3. SMH is characterized by slightly pigmented of these cases of ASMH were shown to have originated from plaques that contain vellus hairs, and SMH is subdivided arrector pili and dartos muscles. Only one case was reported into two types: congenital smooth muscle hamartoma to have originated from vascular smooth muscle cells. A 21 (CSMH) and acquired smooth muscle hamartoma (ASMH)1-3. year-old woman presented with a tender pigmented nodule, ASMH is a very rare form of SMH that was first described with numbness, on the sole of her foot, and this lesion had by Wong and Solomon1 in 1985, with only such 10 cases developed over the previous 18 months. -
Records of Pharmaceutical and Biomedical Sciences
REVIEW ARTICLE RECORDS OF PHARMACEUTICAL AND BIOMEDICAL SCIENCES Effect of Exogenous Anabolic Androgenic Steroids on Testosterone/ Epitestosterone Ratio and its Application on Athlete Biological Passport in Egypt Hanem A. Khalil a, Dina M. Abo-Elmatty b, Rosa V. Alemany c, Noha M. Mesbah b a Egyptian Anti-Doping Organization, Cairo, Egypt. b Faculty of Pharmacy, Department of Biochemistry Suez Canal University, Ismailia, Egypt. C Catalonian Anti-Doping Laboratory of Fundacio IMIM, Barcelona, Spain. Abstract Received on: 01.09. 2018 Using the Anabolic Androgenic Steroid (AAS) agents is evident not only Revised on: 21. 10. 2018 within the competitive senior and junior athletes, but also in non-sporting contexts by individuals seeking to „improve‟ their physique. No accurate data Accepted on: 01. 11. 2018 is available for the prevalence of AAS misuse among athletes. Studies suggest that it may be 1–5% of the population; with the prevalence being higher in males. Many studies documented side effects and health hazards with the misuse of anabolic steroids, where these were accused as a cause of Correspondence Author: deaths among athletes. Intake of exogenous anabolic steroids disturbed the Testosterone / Epitestosterone (T/E) ratio causing its evaluation above the Tel:+201270206648. normal level. This review outlines the anabolic steroids, its side effects and E-mail address: health impacts in both the sporting and physique development contexts. It also provides a brief review of the history of AAS as doping agents and [email protected] athlete biological passport. Conclusion: Doping among athletes is a widespread public health and social problem. Many studies have shown that both short- and long-term health complications have consequences and dependencies. -
Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders
(19) TZZ¥Z__T (11) EP 3 045 177 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 20.07.2016 Bulletin 2016/29 A61K 31/565 (2006.01) A61K 31/566 (2006.01) A61K 31/568 (2006.01) A61K 45/06 (2006.01) (2006.01) (2006.01) (21) Application number: 16000349.7 A61K 31/785 A61P 25/00 (22) Date of filing: 26.09.2006 (84) Designated Contracting States: (72) Inventor: Voskuhl, Rhonda R. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Angeles, CA 90024 (US) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (74) Representative: Müller-Boré & Partner Patentanwälte PartG mbB (30) Priority: 26.09.2005 US 720972 P Friedenheimer Brücke 21 26.07.2006 US 833527 P 80639 München (DE) (62) Document number(s) of the earlier application(s) in Remarks: accordance with Art. 76 EPC: This application was filed on 11-02-2016 as a 13005320.0 / 2 698 167 divisional application to the application mentioned 06815626.4 / 1 929 291 under INID code 62. (71) Applicant: The Regents of the University of California Oakland, CA 94607 (US) (54) ESTRIOL THERAPY FOR AUTOIMMUNE AND NEURODEGENERATIVE DISEASES AND DISORDERS (57) The present invention relates to a dosage from comprising estriol and glatiramer acetate polymer-1 for use in the treatment of multiple sclerosis (MS), as well as to a kit comprising estriol and glatiramer acetate polymer-1. EP 3 045 177 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 045 177 A1 Description [0001] This invention was made with Government support under Grant No. -
Gen Anat-Skin
SKIN • Cutis,integument • External covering • Skin+its appendages-- -integumentary system • Largest organ---15 to 20% body mass. LAYERS • Epidermis •Dermis Types • Thick and thin(1-5 mm thick) • Hairy and non hairy Thick skin EXAMPLES • THICK---PALMS AND SOLES BUT ANATOMICALLY THE BACK HAS THICK SKIN. REST OF BODY HAS THIN SKIN • NON HAIRY----PALMS AND SOLES,DORSAL SURFACE OF DISTAL PHALANX,GLANS PENIS,LABIA MINORA,LABIA MAJORA AND UMBLICUS FUNCTIONS • Barrier • Immunologic • Homeostasis •Sensory • Endocrine • excretory EPIDERMIS(layers) • Stratum basale or stratum germinativum • Stratum spinosum • Stratum granulosum • Stratum lucidum • Stratum corneum Type of cells in epidermis and keratinization • Keratinocytes • Melanocytes • Langerhans • Merkels cells DERMIS LAYERS---- 1.PAPILLARY • Dermal papillae • Complementary epidermal ridges or rete ridges • Dermal ridges in thick skin • Hemidesmosomes present both in dermis and epidermis RETICULAR LAYER •DENSE IRREGULAR CONNECTIVE TIISUE Sensory receptors • Free nerve endings • Ruffini end organs • Pacinian and • Meissners corpuscles Blood supply • Fasciocutaneous A • Musculocutaneous A • Direct cutaneous A APPENDAGES • Hair follicle producing hair • Sweat glands(sudoriferous) • Sebaceous glands • Nails Hair follicle • Invagination of epidermis • Parts---infundibulum, isthmus, inferior part having bulb and invagination HAIR follicle layers • Outer and inner root sheath • Types of hair vellus, terminal, club • Phases of growth— anagen, catagen and telogen Hair shaft • Cuticle •Cortex • Medulla -
Reproductive DHEA
Reproductive DHEA Analyte Information - 1 - DHEA Introduction DHEA (dehydroepiandrosterone), together with other important steroid hormones such as testosterone, DHT (dihydrotestosterone) and androstenedione, belongs to the group of androgens. Androgens are a group of C19 steroids that stimulate or control the development and maintenance of male characteristics. This includes the activity of the male sex organs and the development of secondary sex characteristics. Androgens are also precursors of all estrogens, the female sex hormones. DHEA (dehydroepiandrosterone) is the aromatic C19-steroid composed of a 10,13-dimethyl, 3-hydroxy group and 17-ketone. Its chemical name is 3β-hydroxy-5-androsten-17-one, its summary formula is C19H28O2, and its molecular weight (Mr) is 288.4 Da. The structural formulas of DHEA and related androgens are shown in Fig.1 Fig.1: Structural formulas of the most important androgens DHEA Androstenedione Testosterone Dihydrotestosterone There are more than 40 other names used for DHEA, including: (+)-Dehydroisoandrosterone; (3beta, 16alpha)-3,16-dihydroxy-androst-5-en- 17-one; 5,6-Dehydroisoandrosterone; 17-Chetovis, 17-Hormoforin, Andrestenol, Diandron, Prasterone and so on. As DHEA is very closely connected with its sulfate form DHEA-S, both hormones are mentioned together in the following text. Biosynthesis DHEA is the steroid hormone belonging to the weak androgens. DHEA and DHEA-S are the major C19 steroids produced from cholesterol by the zona reticularis of the adrenal cortex (Fig.2). DHEA is also produced in small quantities in the gonads (testis and ovary3,8,14), in adipose tissue and in the brain. From this point of view DHEA belongs to the neurosteroids22. -
Steroids and Other Appearance and Performance Enhancing Drugs (Apeds) Research Report
Research Report Revised Febrero 2018 Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report Table of Contents Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report Introduction What are the different types of APEDs? What is the history of anabolic steroid use? Who uses anabolic steroids? Why are anabolic steroids misused? How are anabolic steroids used? What are the side effects of anabolic steroid misuse? How does anabolic steroid misuse affect behavior? What are the risks of anabolic steroid use in teens? How do anabolic steroids work in the brain? Are anabolic steroids addictive? How are anabolic steroids tested in athletes? What can be done to prevent steroid misuse? What treatments are effective for anabolic steroid misuse? Where can I get further information about steroids? References Page 1 Steroids and Other Appearance and Performance Enhancing Drugs (APEDs) Research Report Esta publicación está disponible para su uso y puede ser reproducida, en su totalidad, sin pedir autorización al NIDA. Se agradece la citación de la fuente, de la siguiente manera: Fuente: Instituto Nacional sobre el Abuso de Drogas; Institutos Nacionales de la Salud; Departamento de Salud y Servicios Humanos de los Estados Unidos. Introduction Appearance and performance enhancing drugs (APEDs) are most often used by males to improve appearance by building muscle mass or to enhance athletic performance. Although they may directly and indirectly have effects on a user’s mood, they do not produce a euphoric high, which makes APEDs distinct from other drugs such as cocaine, heroin, and marijuana. However, users may develop a substance use disorder, defined as continued use despite adverse consequences.